Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology

Current Drug Metabolism

Volumn 13, Issue 7, 2012, Pages 1007-1011

  Zhang, Li ^a   Yang, Huiyi ^b   Zhao, Yanwei ^a   Liu, Wenchao ^c   Wu, Shiyang ^b   He, Jiaying ^b   Luo, Xiaodi ^b   Zhu, Zeyao ^b   Xu, Jiasen ^b   Zhou, Qinghua ^d   Ren Heidenreich, Lifen ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SurExam Bio Tech Co Ltd   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

EGFR; Exon 19 deletions and L858R; Mutant enriched liquidchip; NSCLC; Somatic mutation; Targeted therapy

Indexed keywords

ERLOTINIB; GEFITINIB; ICOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CROSS REACTION; DNA DETERMINATION; DNA SEQUENCE; EGFR GENE; EXON; FEMALE; GENE DELETION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTANT ENRICHED LIQUIDCHIP TECHNOLOGY; POLYMERASE CHAIN REACTION; RECEPTOR GENE; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; TECHNOLOGY; WILD TYPE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 84865728996     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012802138660     Document Type: Article

References (16)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer. J. Clin., 2005, 55(2), 74-108.
2. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol., 2003, 21(12), 2237-2246.
3. Huang, S.F.; Liu, H.P.; Li, L.H.; Ku, Y.C.; Fu, Y.N.; Tsai, H.Y.; Chen, Y.T.; Lin, Y.F.; Chang, W.C.; Kuo, H.P.; Wu, Y.C.; Chen, Y.R.; Tsai, S.F. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res., 2004, 10(24), 8195-8203.
4. Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med., 2008, 359(13), 1367-1380.
5. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350(21), 2129-2139.
6. Ladanyi, M.; Pao, W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod. Pathol., 2008, 21 Suppl 2, S16-22.
7. Board, R.E.; Thelwell, N.J.; Ravetto, P.F.; Little, S.; Ranson, M.; Dive, C.; Hughes, A.; Whitcombe, D. Multiplexed assays for detection of mutations in PIK3CA. Clin. Chem., 2008, 54(4), 757-760.
8. Asano, H.; Toyooka, S.; Tokumo, M.; Ichimura, K.; Aoe, K.; Ito, S.; Tsukuda, K.; Ouchida, M.; Aoe, M.; Katayama, H.; Hiraki, A.; Sugi, K.; Kiura, K.; Date, H.; Shimizu, N. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin. Cancer Res., 2006, 12(1), 43-48.
9. Inukai, M.; Toyooka, S.; Ito, S.; Asano, H.; Ichihara, S.; Soh, J.; Suehisa, H.; Ouchida, M.; Aoe, K.; Aoe, M.; Kiura, K.; Shimizu, N.; Date, H. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res., 2006, 66(16), 7854-7858.
10. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; Van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 2000, 92(3), 205-216.
11. Dunbar, S.A.; Jacobson, J.W. Application of the luminex LabMAP in rapid screening for mutations in the cystic fibrosis transmembrane conductance regulator gene: A pilot study. Clin. Chem., 2000, 46(9), 1498-1500.
12. Klebig, F.; Fischer, C.; Petri, S.; Gerull, H.; Wagener, C.; Tschentscher, P. Limitations in molecular detection of lymph node micrometastasis from colorectal cancer. Diagn. Mol. Pathol., 2007, 16(2), 91-95.
13. Sequist, L.V.; Martins, R.G.; Spigel, D.; Grunberg, S.M.; Spira, A.; Janne, P.A.; Joshi, V.A.; McCollum, D.; Evans, T.L.; Muzikansky, A.; Kuhlmann, G.L.; Han, M.; Goldberg, J.S.; Settleman, J.; Iafrate, A.J.; Engelman, J.A.; Haber, D.A.; Johnson, B.E.; Lynch, T.J. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol., 2008, 26(15), 2442-2449.
14. Wu, J.Y.; Yu, C.J.; Yang, C.H.; Wu, S.G.; Chiu, Y.H.; Gow, C.H.; Chang, Y.C.; Hsu, Y.C.; Wei, P.F.; Shih, J.Y.; Yang, P.C. First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am. J. Respir. Crit. Care Med., 2008, 178(8), 847-853.
15. Yang, C.H.; Yu, C.J.; Shih, J.Y.; Chang, Y.C.; Hu, F.C.; Tsai, M.C.; Chen, K.Y.; Lin, Z.Z.; Huang, C.J.; Shun, C.T.; Huang, C.L.; Bean, J.; Cheng, A.L.; Pao, W.; Yang, P.C. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol., 2008, 26(16), 2745-2753.
16. Do, H.; Krypuy, M.; Mitchell, P.L.; Fox, S.B.; Dobrovic, A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer, 2008, 8, 142.